The Cystic Fibrosis Foundation (CFF) states that inhaled tobramycin is one of the most widely used treatments for people with cystic fibrosis (CF).
TOBI has been available to treat Pseudomonas aeruginosa in the lungs of people with CF for over a decade. It is approved for people aged 6 and over with a lung function within a certain range.
In clinical studies, people with CF who treated Pseudomonas aeruginosa with TOBI saw their FEV1 improve by 10% on average from baseline compared with a 2% decline in FEV1 in patients receiving placebo at 20 weeks. People who did not take TOBI had worse lung function at the end of the studies
In clinical studies, people with CF treated with TOBI had 37% fewer days in the hospital versus placebo (5.1 days vs 8.1 days, respectively)
Clinical studies show that when people with CF treat Pseudomonas aeruginosa with TOBI, there are 32% fewer days receiving IV antipseudomonal antibiotics versus placebo (9.6 and 14.1 days, respectively) than people who did not take TOBI
Eligible Patients Pay only a $10 Co-Pay for TOBILEARN more